20/20 is not the whole story

What 20/20 does, and does not, tell you

Uncorrected distance acuity measures the smallest high-contrast letters a person can resolve without glasses. Researchers use it because it is standardized, familiar and closely tied to the main promise of refractive surgery: clearer distance vision without correction.

The chart is usually bright and the letters are black. Real life is messier. It does not fully capture a wet road at night, halos around headlights, focus that comes and goes, near vision, discomfort or the effort it takes to keep an image clear. Best-corrected acuity matters as well. Losing a line that glasses cannot restore is different from ending up with a small prescription.

A convincing results table needs more than a 20/20 column. Look for refractive accuracy, loss of corrected vision, symptoms, retreatment and what patients themselves said about the result. If a paper reports only acuity, the rest of the story is missing.

A study gives you an estimate, not a forecast

Every result carries the fingerprints of its study design. Who was allowed in? Which device did the surgeons use? Did the analysis count both eyes? How long did it follow people, and how many came back? You need those details before deciding how much weight to give the headline number.

The denominator matters more than it gets credit for. One event in 100 eyes and 100 events in 10,000 eyes are both 1%, but the larger estimate is far less fragile. Likewise, seeing no cases in a small study does not mean the risk is zero. Rare complications demand large groups and good follow-up.

Time can quietly ruin a comparison too. Three-month results should not be lined up against one-year results as if the visits were equivalent. Nor should a low-myopia cohort become a prediction for someone with a much stronger prescription. Keeping the population and follow-up beside the result is basic context, not statistical fussiness.

What patient stories are genuinely good at

Clinical visits take snapshots. A detailed first-person account can fill in the days between them: blur that builds through a workday, fear around the first night drive, a cupboard filling with eye drops, or the moment the result finally begins to feel worth it.

That texture is valuable. It is not an incidence rate. People choose whether to post, communities attract particular experiences and the same story may be cross-posted in several places. Sometimes the diagnosis in a post is a guess. A story can alert you to something that happens; it cannot tell you how often it happens.

The limitation cuts both ways. A glowing account is still one account. It tells you that this person was happy, not that someone with a different prescription, eye surface or device should expect the same ending.

A sensible way to read both

Begin with the studies. They show what researchers measured, the range of results and how certain those results are. Then read patient accounts. They are good at raising questions that never made it into a results table. After that, go back to the research and see whether anyone measured the concern properly.

Say halos appear again and again in community posts. Counting those posts will not produce a trustworthy rate. A better next step is to find a study that asked about halos in a defined way at a stated follow-up, then check whether its patients resemble the person making the decision.

Sometimes the studies have no answer. Call that an evidence gap. “We did not find this measured” is a perfectly respectable conclusion, and much better than dismissing the stories or pretending they establish frequency.

Before you repeat an impressive number

Run through these five questions. It takes less than a minute and catches most misleading comparisons.

• Population: Who was actually included and excluded?
• Procedure and device: What exactly was done, with what technology?
• Outcome definition: What did “success,” “dry eye” or “satisfied” mean?
• Timepoint: When was the result measured?
• Denominator and follow-up: How many eyes or patients contributed, and how many were missing?

Good evidence should make your questions sharper

No paper can remove the uncertainty from elective surgery. What evidence can do is show you where the uncertainty sits: eligibility, visual quality, recovery, long-term follow-up or the chance of needing more treatment.

On this site, published cohorts and community experiences stay in separate lanes. Both can inform the same decision. They just earn their credibility in different ways.